IPO Trending
SUPRIYAEQ / NSE, BSEListed

Supriya Lifescience Limited

Supriya Lifescience is a manufacturer of Active Pharmaceutical Ingredients (APIs), producing 38 APIs across therapeutic segments such as antihistamines, analgesics, anaesthetics, vitamins, anti-asthmatics, and anti-allergics. Between FY 2017 and FY 2021, it was the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India, and one of the largest exporters of Salbutamol Sulphate in FY 2021. The company exports to 86 countries, serving 1,296 customers, including 346 distributors, across Europe, Latin America, Asia, and North America. Its modern manufacturing facility in Maharashtra spans 23,806 sq. m with a reactor capacity of 547 KL/day and seven clean rooms. Supriya Lifescience has acquired an additional 12,551 sq. m plot for expansion and holds regulatory approvals from USFDA, EDQM, TGA-Australia, KFDA-Korea, PMDA-Japan, NMPA-China, and Health Canada for its API exports.

₹265 - ₹274Open
Listed Price421.00
Listing Gain+53.65%
Review-Analyst Consensus Verdict

May apply

No review summary is available yet.

Apply
00%
May Apply
00%
Neutral
00%
Avoid
00%
Not Rated
00%
No IPO review records are available for this issue yet.